Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from AxoGen ( (AXGN) ).
On January 12, 2026, Axogen reported preliminary unaudited results indicating that fourth-quarter 2025 revenue is expected to be about $59.9 million, up 21.3% year over year, while full-year 2025 revenue is projected at approximately $225.2 million, a 20.2% increase from 2024, supported by broad product portfolio demand, targeted commercial execution in extremities and head and neck markets, and growing adoption of its Resensation procedure. The company expects fourth-quarter and full-year 2025 gross margins above 74%, despite roughly $1.9 million in one-time costs tied to the U.S. FDA’s December 3, 2025 approval of Avance as a biologic therapeutic, most of which are non-cash stock-compensation charges, and it ended 2025 with an estimated $45.5 million in cash and investments—about $6 million more than a year earlier—signaling improved financial strength and reinforcing its strategic positioning in the peripheral nerve repair market; Axogen also posted an updated corporate presentation for use with investors on the same date.
The most recent analyst rating on (AXGN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.
Spark’s Take on AXGN Stock
According to Spark, TipRanks’ AI Analyst, AXGN is a Neutral.
AxoGen’s overall stock score is driven by strong earnings call results and significant corporate events, particularly the FDA approval for Avance Nerve Scaffold. Technical analysis supports a bullish outlook, although valuation concerns due to negative profitability metrics slightly dampen the score.
To see Spark’s full report on AXGN stock, click here.
More about AxoGen
Axogen, Inc. (NASDAQ: AXGN) is a global leader in developing and marketing surgical solutions for the restoration of peripheral nerve function, focused on the science, development and commercialization of technologies for peripheral nerve repair. Its product portfolio, including Avance acellular nerve allograft, Axoguard nerve repair solutions and Avive+ Soft Tissue Matrix, is marketed across the United States, Canada, major European markets and other countries, with a mission to make nerve repair the expected standard of care through research, education and collaboration with surgeons and healthcare providers.
Average Trading Volume: 871,053
Technical Sentiment Signal: Buy
Current Market Cap: $1.54B
Find detailed analytics on AXGN stock on TipRanks’ Stock Analysis page.